Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), received approval from the National Medical Products Administration for the clinical trial application of its injectable drug GenSci136, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a self-developed Class 1 biological product [1] - The clinical trial application for GenSci136 has been approved for use in treating IgAN and generalized myasthenia gravis [1]

一、并购 1、海南矿业：拟通过发行股份及支付现金购买丰瑞氟业69.90%股权，股票复牌。 2、埃夫特：拟购买盛普股份100%股份，股票复牌；盛普股份是一家专注于精密流体控制设备研发企 业，其产品核心应用于新能源、汽车电子等高端制造领域，涵盖光伏组件涂胶机、动力电池电芯及电池 包涂胶设备等领域。 二、回购、增持 1、恺英网络：拟以1亿元-2亿元回购，回购价格不超过36.91元/股。 2、电连技术：拟以1亿元-2亿元回购，拟回购价格不超过69.72元/股。 3、博威合金：控股股东博威集团拟增持1亿至1.5亿元。 三、对外投资、日常经营 1、源杰科技：拟投资建设光电通讯半导体芯片和器件研发生产基地二期项目，投资总额约为12.51亿 元。 2、盟固利：拟投资9.29亿元建设年产3万吨锂离子电池正极材料项目。 3、威海广泰：拟收购山东机场投资和威海机场持有安泰装备的全部股份，收购后公司持股比例由65% 增加至100%，安泰装备变成公司全资子公司。 4、当升科技：与辉能科技签署策略合作框架协议。 东威科技：2025年净利润1.29亿元，同比增长86.81%。 晚间公告 7、交控科技：与Metro Trains West ...

证券代码：000661 证券简称：长春高新 公告编号：2026-009 审批结论：经审查，同意本品开展临床试验 长春高新技术产业（集团）股份有限公司 关于子公司注射用 GenSci136 境内生产药品注册临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，金赛药业注射用 GenSci136 境 内生产药品注册临床试验申请获得批准，现将相关情况公告如下： 一、药品的基本情况 产品名称：注射用 GenSci136 申请事项：境内生产药品注册临床试验 受理号：CXSL2600033 申请人：长春金赛药业有限责任公司 适应症：用于免疫球蛋白 A 肾病（IgAN） 二、药品的其它情况 注射用 GenSci136 是金赛药业自主研发的一款治疗用生物制品 1 类药物，拟 用于治疗免疫球蛋白 A 肾病（IgAN）。 IgAN 是全球范围内最常见的原发性肾小球肾炎之一，在 ...

在2026中国滑雪度假区竞争力推荐榜单中，我市的庙香山滑雪场、莲花山滑雪场、天定山滑雪场与全国 47家滑雪度假区入选"综合维度滑雪旅游度假区"。此外，按照服务设施、服务能力、服务质量、消费偏 好满意度等12个细分维度，长春净月潭滑雪场以历史悠久、适合初学者的特色入选推荐榜单。 2月7日，"冰雪旅游场地装备与智能服务技术"文化和旅游部重点实验室在长春市召开发布会，揭 晓"2026中国滑雪度假区竞争力推荐榜暨滑雪旅游十佳城市推荐榜"：长春市成功入选"滑雪旅游十佳城 市"推荐榜。此次，长春、吉林、通化与哈尔滨、沈阳、乌鲁木齐、张家口、阿勒泰、呼和浩特、兰州 十个城市入选中国"滑雪旅游十佳城市推荐榜"。 本次共有全国25个省、市、自治区的367家滑雪度假区和滑雪场参与了本次榜单推荐，占全国滑雪场和 滑雪度假区总数的五分之二。 据了解，"冰雪旅游场地装备与智能服务技术"文化和旅游部重点实验室成立于2021年，经国家文化和旅 游部批准认定，依托吉林大学建设，是全国冰雪旅游领域唯一的部级重点实验室。此次发布推荐榜单是 实验室历时2年时间完成的又一项重要科研成果。 来 源：长春新闻 ...

Core Viewpoint - The company is currently experiencing short-term profit impacts due to increased investments in new product development and global expansion, but management remains focused on enhancing core competitiveness through innovation in the biopharmaceutical sector to achieve sustainable high-quality growth [1] Group 1 - The company is investing heavily in new product layouts and global expansion, which is affecting net profit in the short term [1] - Management emphasizes a commitment to focusing on the biopharmaceutical core business and deepening innovation-driven strategies [1] - The goal is to continuously improve the company's core competitiveness for stable and high-quality development in the long run [1]

Group 1 - The core viewpoint of the article is that Changchun Gaoxin (000661) emphasizes strict adherence to its compensation system for assessing the salaries of relevant personnel [1] Group 2 - The company responded to investor inquiries on its interactive platform regarding its compensation practices [1]

Core Viewpoint - Changchun High-tech emphasizes its commitment to balancing operational development and shareholder returns through strict internal control and auditing mechanisms for all expenditures [2] Group 1: Financial Management - The company states that its three major expenses are focused on the development of the biopharmaceutical industry, research and innovation, market expansion, and compliance operations [2] - All expenditures are subject to strict internal control approval, audit supervision, and information disclosure mechanisms [2] Group 2: Shareholder Returns - The company adheres to profit distribution rules while considering the industry's development stage for comprehensive planning [2] - Future efforts will focus on enhancing the precision of expense management and improving capital efficiency [2] - The company aims to balance long-term development of its core business with reasonable returns for shareholders, ensuring the interests of all shareholders are maintained [2]

Group 1 - Changchun High-tech is expected to incur a loss of 1 billion in the fourth quarter due to product price adjustments, while investing over 2 billion annually in R&D to reduce reliance on growth hormones [1] - Vanke's losses are deepening, with a projected loss of 82 billion by 2025, and a bond extension of 6.8 billion as it seeks financial support [1] - GAC Group has issued a rare profit warning, expecting a loss between 8 billion to 9 billion, as CEO Feng Xingya emphasizes the "three major battles" for a turnaround [1] Group 2 - Nanhai Rural Commercial Bank was fined 3.8 million, with its net interest margin dropping to 1.15% after eight years of no results in the A-share market [1] - Yuanji Food is closing one out of every three new stores, with related party transactions amounting to 130 million involving the wife of its founder [1] - "Cheese Queen" Chai Xiu faced backlash from aggressive marketing strategies, leading to a 70% drop in the stock price of Miao Ke Lan Duo, with Mengniu taking full control [1] Group 3 - Zijin Mining is investing an additional 28 billion in overseas ventures, projecting a profit of 51 billion by 2025, with its market value stabilizing above 1 trillion [1] - Hunan Gold is restructuring 2.7 billion in assets to increase resource reserves, benefiting from rising prices of antimony and tungsten, achieving record profits exceeding 1.27 billion [1] - A major shareholder, Yu Han, was fined over 1 billion for manipulating stock prices, while Doctor Glasses spent 50 million on traffic acquisition but only 3 million on R&D [1] Group 4 - SAIC-GM-Wuling's debt ratio has risen to 85.24%, despite a 20.5% increase in sales, still falling short by 535,000 units compared to peak levels [1] - Su Nong Bank's "village reform branch" faced 18% opposition from minority shareholders, with total assets at 231.1 billion and revenue growth of only 0.41% [1] - Mingming Hen Mang opened 21,000 stores and distributed a pre-IPO dividend of 526 million, with Zhao Ding cashing out 130 million [1] Group 5 - Xibei's new round of financing received support from Zhang Yong and Hu Xiaoming, but the dream of a 100 billion market value faces challenges [1] - China Duty Free Group is acquiring 2.7 billion to build an international business platform, with performance declining for six consecutive quarters, and collaboration with LVMH remains to be observed [1] - Hikvision has returned to growth with an annual profit of 14.2 billion, enhancing cash collection management and recovering 13.7 billion in nine months [1]

Core Viewpoint - Changchun High-tech, a leading company in the growth hormone industry, is experiencing a significant decline in net profit, with a forecasted drop of 91.48% to 94.19% for 2025 compared to the previous year [1] Group 1: Financial Performance - In the third quarter of 2025, Changchun High-tech reported a revenue of 9.807 billion yuan, a decrease of 5.6% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year [1] - The peak net profit for Changchun High-tech was 4.532 billion yuan in 2023, but it fell by 43% in 2024, indicating a continuing downward trend into 2025 [1] - The company anticipates a net profit of 150 million to 200 million yuan for 2025, marking a substantial decline from previous years [1] Group 2: Market and Product Dynamics - The sales of growth hormones are influenced by the number of adolescents and newborns, with increased competition also impacting performance [2] - Changchun High-tech's long-acting growth hormone and related products have been included in the new national medical insurance directory, effective January 1, 2026, with a price reduction of approximately 75% [2] - The company has adjusted its sales policies and pricing in response to industry policy changes and market conditions, which has contributed to reduced revenue and net profit [2] Group 3: Subsidiary Performance - Changchun High-tech's subsidiary, Baike Biological, is expected to report a net loss of 220 million to 280 million yuan for 2025, marking its first loss since going public, primarily due to intensified competition and decreased vaccination willingness [3] - The sales revenue of the shingles vaccine from Baike Biological has already seen a decline of 71.54% in 2024, continuing to be negatively affected in 2025 [4] - Factors affecting the shingles vaccine sales include public awareness of the disease, vaccination willingness, and increased market competition, leading to unsold inventory and returns [4]

Group 1 - The core announcement is that Changchun High-tech has received acceptance for the clinical trial application of its subsidiary Changchun Jinsai Pharmaceutical's injectable GenSci136 for domestic drug registration [1] - GenSci136 is a Class 1 therapeutic biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of generalized myasthenia gravis (gMG) [2] - If the clinical trial application progresses smoothly, it will help the company expand its business structure, optimize its product structure, and enhance its core competitiveness [2]